EF
MRNA icon

Empirical Finance’s Moderna MRNA Stock Holding History

Empirical Finance’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$457K Sell
8,995
-9
-0.1% -$420 0.02% 421
2025
Q4 		$266K Sell
9,004
-399
-4% -$10.8K 0.01% 463
2025
Q3 		$243K Buy
9,403
+103
+1% +$2.87K 0.01% 494
2025
Q2 		$257K Buy
9,300
+85
+0.9% +$2.24K 0.01% 486
2025
Q1 		$261K Buy
9,215
+624
+7% +$22.1K 0.02% 477
2024
Q4 		$357K Sell
8,591
-22
-0.3% -$1.05K 0.02% 447
2024
Q3 		$576K Buy
8,613
+334
+4% +$30.7K 0.03% 394
2024
Q2 		$983K Sell
8,279
-696
-8% -$88.1K 0.06% 269
2024
Q1 		$956K Buy
8,975
+399
+5% +$40.2K 0.06% 286
2023
Q4 		$853K Buy
8,576
+190
+2% +$16K 0.06% 287
2023
Q3 		$866K Buy
8,386
+1,157
+16% +$129K 0.06% 264
2023
Q2 		$878K Buy
7,229
+1,215
+20% +$162K 0.07% 261
2023
Q1 		$924K Buy
6,014
+700
+13% +$115K 0.09% 226
2022
Q4 		$955K Buy
5,314
+633
+14% +$104K 0.1% 209
2022
Q3 		$554K Buy
4,681
+1,382
+42% +$210K 0.07% 276
2022
Q2 		$471K Buy
3,299
+358
+12% +$51.2K 0.06% 287
2022
Q1 		$507K Buy
2,941
+749
+34% +$126K 0.06% 305
2021
Q4 		$557K Buy
+2,192
New +$641K 0.07% 274

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Empirical Finance's MRNA Position: Q1 2026 in Review

Empirical Finance reduced its Moderna (MRNA) stake by 0.1% in Q1 2026, selling an estimated $420 and leaving 8,995 shares worth $457K. The position accounts for 0.02% of the portfolio, ranked #421.

Empirical Finance first reported a position in MRNA in Q4 2021 and has held it in 18 quarters since. The position peaked at $983K in Q2 2024. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Empirical Finance held 8,995 shares of Moderna worth $457K as of Q1 2026.
  • Empirical Finance sold 9 Moderna shares in Q1 2026, an estimated $420.
  • Moderna made up 0.02% of Empirical Finance's portfolio in Q1 2026, its #421 holding.
  • Empirical Finance first reported a position in Moderna in Q4 2021 and has held it in 18 quarters since.
  • Empirical Finance's Moderna position peaked at $983K in Q2 2024.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Empirical Finance's 13F filing for Q1 2026, filed 14 May 2026.